Elicio Therapeutics, Inc. Cost of Revenue
Elicio Therapeutics, Inc. (ELTX) reported Cost of Revenue of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-17.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2023-03-17
- Elicio Therapeutics, Inc. cost of revenue for the quarter ending 2021-12-31 was $433.00K, a 243.65% increase year-over-year.
- Elicio Therapeutics, Inc. cost of revenue for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. cost of revenue for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. cost of revenue for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. cost of revenue for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Elicio Therapeutics, Inc. cost of revenue for fiscal 2021 was $433.00K, a 63.61% decline from fiscal 2020.
- Elicio Therapeutics, Inc. cost of revenue for fiscal 2020 was $1.19M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-17 | |||
| 2021-12-31 | $433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $433.00K derived: sum of 2 quarters · filed 2023-03-17 | $433.00K derived: sum of 3 quarters · filed 2023-03-17 | $433.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | $126.00K derived: sum of 4 quarters · filed 2022-03-30 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $126.00K derived: sum of 3 quarters · filed 2022-03-30 | $474.00K derived: sum of 4 quarters · filed 2022-03-30 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-17 | $126.00K derived: sum of 2 quarters · filed 2022-03-30 | $474.00K derived: sum of 3 quarters · filed 2022-03-30 | $807.00K derived: sum of 4 quarters · filed 2022-03-30 |
| 2020-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $474.00K derived: sum of 2 quarters · filed 2022-03-30 | $807.00K derived: sum of 3 quarters · filed 2022-03-30 | $1.19M 10-K · filed 2022-03-30 |
| 2020-09-30 | $348.00K 10-Q · filed 2021-11-12 | $681.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.06M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $333.00K 10-Q · filed 2021-08-12 | $716.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $383.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |